Latest Period
Q1 2026
Security Snapshot
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) Institutional Ownership
CUSIP: 86150R107
13F Institutional Holders and Ownership History from Q2 2019 to Q1 2026
Institutions Reporting
196
Shares (Excl. Options)
71,107,852
Price
$32.56
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- STOK on Nasdaq
- Shares outstanding
- 58,810,778
- Price per share
- $32.42
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 71,107,852
- Total reported value
- $2,314,610,833
- % of total 13F portfolios
- 0.01%
- Share change
- +3,993,162
- Value change
- +$131,278,501
- Number of holders
- 196
- Price from insider filings
- $32.42
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 86150R107.
- 196 institutions reported positions in Q1 2026.
- 11 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 183 to 196 between Q4 2025 and Q1 2026.
- Reported value moved from $2,126,072,755 to $2,314,610,833.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 196 institutions filings for Q1 2026.
Security key
86150R107
Latest holder period
Q1 2026
13F holders
196
13D/G owners
11
CIK / CUSIP context first
Open Q1 2026 holders
STOK full holder history
Stoke Therapeutics, Inc. SEC filings
Stoke Therapeutics, Inc. company facts
Stoke Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 86150R107:
Significant Owners of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 9.9% | -0.9% | $208,227,353 | +$22,110,697 | 5,940,866 | +12% | RTW Investments, LP | 31 Mar 2026 |
| FMR LLC | 9.8% | -21% | $177,773,201 | -$40,123,708 | 5,600,920 | -18% | FMR LLC | 31 Dec 2025 |
| Lynx1 Capital Management LP | 8.1% | $154,438,279 | 4,763,673 | Lynx1 Capital Management LP | 31 Mar 2026 | |||
| Redmile Group, LLC | 6.7% | -16% | $145,952,406 | -$7,423,976 | 4,164,120 | -4.8% | Redmile Group, LLC | 31 Mar 2026 |
| BlackRock, Inc. | 6.8% | +17% | $87,769,558 | +$14,428,761 | 3,732,540 | +20% | BlackRock, Inc. | 30 Sep 2025 |
| MORGAN STANLEY | 6.5% | $32,588,288 | 3,426,739 | Morgan Stanley | 31 Dec 2024 | |||
| BAKER BROS. ADVISORS LP | 5.8% | $105,906,763 | 3,336,697 | Baker Bros. Advisors LP | 31 Dec 2025 | |||
| TORONTO DOMINION BANK | 5.4% | -6.7% | $111,222,693 | 3,173,258 | 0% | The Toronto-Dominion Bank | 31 Mar 2026 | |
| WELLINGTON MANAGEMENT GROUP LLP | 5.2% | $108,504,285 | 3,095,700 | Wellington Management Group LLP | 31 Mar 2026 | |||
| BlackRock Portfolio Management LLC | 4.7% | -8% | $28,946,115 | -$2,192,358 | 2,550,341 | -7% | BlackRock Portfolio Management LLC | 30 Jun 2025 |
| Skorpios Trust | 4.1% | -32% | $29,037,049 | -$12,870,000 | 2,256,181 | -31% | Montrago Trustees Ltd | 22 Aug 2025 |
As of 31 Mar 2026, 196 institutional investors reported holding 71,107,852 shares of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK). This represents 121% of the company’s total 58,810,778 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) together control 103% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RTW INVESTMENTS, LP | 9.6% | 5,623,525 | +1.4% | 1.8% | $183,101,974 |
| BlackRock, Inc. | 9.2% | 5,385,714 | +3.3% | 0% | $175,358,848 |
| FMR LLC | 9.2% | 5,383,666 | -3.9% | 0.01% | $175,292,165 |
| Lynx1 Capital Management LP | 8.1% | 4,763,673 | -12% | 25% | $155,105,193 |
| Redmile Group, LLC | 7.1% | 4,164,120 | +3.2% | 9% | $135,583,747 |
| MORGAN STANLEY | 5.8% | 3,423,280 | -3.5% | 0.01% | $111,461,996 |
| BAKER BROS. ADVISORS LP | 5.7% | 3,336,697 | 0% | 0.62% | $108,642,854 |
| TORONTO DOMINION BANK | 5.4% | 3,173,258 | 0% | 0.2% | $103,321,280 |
| WELLINGTON MANAGEMENT GROUP LLP | 5.3% | 3,095,700 | +321% | 0.02% | $100,795,992 |
| BVF INC/IL | 4.3% | 2,547,557 | +12% | 2.6% | $82,948,456 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4% | 2,355,603 | 0% | 0% | $76,698,434 |
| STATE STREET CORP | 3.9% | 2,276,512 | -8.9% | 0% | $74,123,231 |
| Siren, L.L.C. | 3.4% | 1,995,347 | -11% | 1.8% | $64,968,498 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 3.3% | 1,934,171 | +419% | 0.01% | $62,977,000 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.1% | 1,823,500 | 0% | 0.7% | $59,373,160 |
| JANUS HENDERSON GROUP PLC | 2.7% | 1,612,781 | +11% | 0.03% | $52,455,703 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.2% | 1,322,260 | +13% | 0% | $43,060,709 |
| Polar Capital Holdings Plc | 1.9% | 1,132,511 | -11% | 0.16% | $36,874,558 |
| DIMENSIONAL FUND ADVISORS LP | 1.7% | 989,936 | +20% | 0.01% | $32,228,581 |
| Assenagon Asset Management S.A. | 1.5% | 907,015 | -26% | 0.05% | $29,532,408 |
| GOLDMAN SACHS GROUP INC | 1.4% | 830,702 | -27% | 0% | $27,047,658 |
| MPM BIOIMPACT LLC | 1.3% | 767,038 | -0.42% | 1.9% | $24,974,757 |
| Opaleye Management Inc. | 1.2% | 700,000 | +0.72% | 3.2% | $22,792,000 |
| Troluce Capital Advisors LLC | 1.1% | 652,800 | 2.2% | $21,255,168 | |
| BAILLIE GIFFORD & CO | 0.98% | 575,182 | +133% | 0.02% | $18,727,927 |
Institutional Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 71,107,852 | $2,314,610,833 | +$131,278,501 | $32.56 | 196 |
| 2025 Q4 | 66,984,195 | $2,126,072,755 | +$58,211,085 | $31.74 | 183 |
| 2025 Q3 | 67,691,438 | $1,574,062,054 | +$64,324,837 | $23.50 | 151 |
| 2025 Q2 | 65,548,147 | $743,993,162 | +$30,166,679 | $11.35 | 133 |
| 2025 Q1 | 63,384,229 | $421,575,155 | +$30,343,505 | $6.65 | 124 |
| 2024 Q4 | 58,062,255 | $640,428,361 | -$5,638,079 | $11.03 | 129 |
| 2024 Q3 | 58,214,468 | $715,466,637 | -$45,762,031 | $12.29 | 116 |
| 2024 Q2 | 61,301,002 | $828,175,296 | +$96,412,204 | $13.51 | 114 |
| 2024 Q1 | 54,138,461 | $730,867,238 | +$123,726,512 | $13.50 | 101 |
| 2023 Q4 | 45,032,645 | $236,869,874 | +$6,784,370 | $5.26 | 81 |
| 2023 Q3 | 43,943,299 | $173,133,829 | -$18,481,683 | $3.94 | 96 |
| 2023 Q2 | 46,534,137 | $494,657,865 | +$21,008,744 | $10.63 | 98 |
| 2023 Q1 | 44,636,031 | $371,816,808 | +$35,289,257 | $8.33 | 97 |
| 2022 Q4 | 40,284,847 | $371,831,189 | -$22,554,117 | $9.23 | 106 |
| 2022 Q3 | 42,272,703 | $544,351,939 | -$11,748,534 | $12.84 | 99 |
| 2022 Q2 | 43,072,954 | $569,403,611 | +$19,595,358 | $13.21 | 88 |
| 2022 Q1 | 41,334,322 | $870,301,369 | +$123,934,287 | $21.05 | 96 |
| 2021 Q4 | 35,383,061 | $848,561,802 | +$26,332,046 | $23.99 | 91 |
| 2021 Q3 | 19,355,184 | $492,398,465 | -$30,803,526 | $25.44 | 89 |
| 2021 Q2 | 20,216,239 | $680,314,450 | -$703,085,149 | $33.66 | 96 |
| 2021 Q1 | 38,422,385 | $1,492,282,987 | -$15,747,693 | $38.84 | 104 |
| 2020 Q4 | 38,644,696 | $2,393,196,414 | +$252,468,837 | $61.93 | 93 |
| 2020 Q3 | 34,632,372 | $1,159,842,494 | +$2,937,942 | $33.49 | 89 |
| 2020 Q2 | 34,945,268 | $824,517,432 | +$9,797,711 | $23.83 | 70 |
| 2020 Q1 | 34,562,212 | $791,472,895 | +$23,374,012 | $22.90 | 67 |
| 2019 Q4 | 33,483,529 | $948,191,901 | +$22,388,802 | $28.32 | 64 |
| 2019 Q3 | 15,935,472 | $338,961,585 | +$30,078,348 | $21.49 | 52 |
| 2019 Q2 | 14,232,528 | $409,341,450 | +$409,341,450 | $29.17 | 47 |